<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712787</url>
  </required_header>
  <id_info>
    <org_study_id>M15-570</org_study_id>
    <secondary_id>2018-000268-26</secondary_id>
    <nct_id>NCT03712787</nct_id>
  </id_info>
  <brief_title>An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)</brief_title>
  <official_title>An Extension Study of ABBV-8E12 in Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in&#xD;
      participants with early AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).&#xD;
  </why_stopped>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Study Drug, and Fatal TEAEs</measure>
    <time_frame>From first dose of study drug to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
    <description>Treatment emergent adverse events (TEAEs) are defined as any adverse event (AE) from the time of study drug administration until 20 weeks after discontinuation of study drug. An AE is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE (SAE) is defined as any event that: results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome. Severity of AEs was categorized as mild, moderate, or severe. Relationship of the AE to the study treatment was categorized as having a reasonable possibility or no reasonable possibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology: Number of Participants With Postbaseline Potentially Clinically Significant (PCS) Values</measure>
    <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
    <description>Clinical laboratory PCS criteria were adapted from National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Chemistry: Percentage of Participants With Postbaseline PCS Values</measure>
    <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
    <description>Clinical laboratory PCS criteria were adapted from NCI CTCAE version 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS) During Double-Blind Treatment Period</measure>
    <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
    <description>The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Magnetic Resonance Imaging (MRI) Results: Number of Participants With Cerebral Edemas, New Microhemorrhage(s), and Severe White Matter Disease</measure>
    <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>300 mg/1000 mg Tilavonemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 300 mg tilavonemab in Study M15-566 receive 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks for up to 5.5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg/1000 mg Tilavonemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 1000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2000 mg/2000 mg Tilavonemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received 2000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO/2000 mg Tilavonemab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo (PBO) in Study M15-566 receive 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilavonemab</intervention_name>
    <description>solution for IV infusion</description>
    <arm_group_label>1000 mg/1000 mg Tilavonemab</arm_group_label>
    <arm_group_label>2000 mg/2000 mg Tilavonemab</arm_group_label>
    <arm_group_label>300 mg/1000 mg Tilavonemab</arm_group_label>
    <arm_group_label>PBO/2000 mg Tilavonemab</arm_group_label>
    <other_name>ABBV-8E12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects with early AD who complete Study M15-566 (NCT02880956), meet all&#xD;
             inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment&#xD;
&#xD;
          -  Subject was compliant during participation in Study M15-566 (NCT02880956)&#xD;
&#xD;
          -  Subject has an identified, reliable study partner who has frequent contact with the&#xD;
             subject and who will provide information as to the subject's cognitive and functional&#xD;
             abilities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any significant change in his/her medical condition since&#xD;
             participation in Study M15-566 (NCT02880956) that could interfere with the subject's&#xD;
             participation in Study M15-570, could place the subject at increased risk, or could&#xD;
             confound interpretation of study results&#xD;
&#xD;
          -  More than 8 weeks have elapsed since the subject received his/her last dose of study&#xD;
             drug in Study M15-566 (NCT02880956)&#xD;
&#xD;
          -  The subject is concurrently enrolled in another interventional clinical study&#xD;
             involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>57 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner University of Arizona Medical Center Phoenix /ID# 203959</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Clinical Research /ID# 204000</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd /Id# 204001</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San /ID# 204011</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0633</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research /ID# 203957</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Southwest Florida /ID# 203956</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic /ID# 203995</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. /ID# 203992</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-1044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 204009</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc /ID# 204010</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162-7116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University / Emory Brain Health Center /ID# 203999</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329-2206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroStudies.net, LLC /ID# 204004</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital /ID# 203993</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern IL Univ School of Med /ID# 203952</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University /ID# 203989</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center - Alzheimer's Disease Center /ID# 203960</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center /ID# 203996</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 203954</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Physicians /ID# 204003</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic /ID# 213435</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute /ID# 203953</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital /ID# 203994</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr /ID# 203958</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University /ID# 203997</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Studies LLC /ID# 213183</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital /ID# 204005</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center /ID# 203951</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerwin Research Center /ID# 203998</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital /ID# 204002</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGovern Medical School /ID# 213312</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah /ID# 203991</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Neurology Services /ID# 203990</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Centre for Applied Medical Research /ID# 204903</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Griffith University /ID# 204905</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4222</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health /ID# 204906</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Alzheimer's Res Fou /ID# 204904</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc /ID# 204963</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven /ID# 204965</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Sante CHC - Clinique du MontLegia /ID# 204964</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute /ID# 204121</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program /ID# 204120</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet /ID# 204591</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Services Turku /ID# 205924</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ita-Suomen Yliopisto /ID# 204538</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU di Modena /ID# 203904</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli /ID# 203906</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia /ID# 203905</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli /ID# 203903</name>
      <address>
        <city>Brescia</city>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda /ID# 203901</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 203902</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGM Research Trust /ID# 204907</name>
      <address>
        <city>Burwood</city>
        <zip>8083</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion CITA Alzheimer Fundazioa /ID# 204521</name>
      <address>
        <city>Donostia</city>
        <state>Pais Vasco</state>
        <zip>20009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio ACE /ID# 204520</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 204519</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 204518</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge /ID# 203900</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>171 77</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital Molndal /ID# 203899</name>
      <address>
        <city>Molndal</city>
        <state>Vastra Gotalands Lan</state>
        <zip>431 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <results_first_submitted>August 25, 2022</results_first_submitted>
  <results_first_submitted_qc>August 25, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2022</results_first_posted>
  <last_update_submitted>August 25, 2022</last_update_submitted>
  <last_update_submitted_qc>August 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tilavonemab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03712787/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 30, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03712787/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 364 participants who had completed the parent study (Study M15-566; NCT02880956) were enrolled into this extension study from a total of 57 sites in the United States, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Spain, and Sweden.</recruitment_details>
      <pre_assignment_details>Prior to enrollment, 87 participants had received tilavonemab 300 mg, 97 participants had received tilavonemab 1000 mg, 88 participants had received tilavonemab 2000 mg, and 92 participants had received placebo in the parent study.&#xD;
One enrolled participant did not receive any study drug and was not included in any analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>300 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>1000 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>2000 mg/2000 mg Tilavonemab</title>
          <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>PBO/2000 mg Tilavonemab</title>
          <description>Participants who received placebo (PBO) in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COVID-19 Logistical Restrictions</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COVID-19 Infection</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Data Set: All participants who received at least 1 dose of study drug in M15-570.</population>
      <group_list>
        <group group_id="B1">
          <title>300 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>1000 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>2000 mg/2000 mg Tilavonemab</title>
          <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>PBO/2000 mg Tilavonemab</title>
          <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="91"/>
            <count group_id="B5" value="363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Study Drug, and Fatal TEAEs</title>
        <description>Treatment emergent adverse events (TEAEs) are defined as any adverse event (AE) from the time of study drug administration until 20 weeks after discontinuation of study drug. An AE is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE (SAE) is defined as any event that: results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome. Severity of AEs was categorized as mild, moderate, or severe. Relationship of the AE to the study treatment was categorized as having a reasonable possibility or no reasonable possibility.</description>
        <time_frame>From first dose of study drug to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
        <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>1000 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2000 mg/2000 mg Tilavonemab</title>
            <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO/2000 mg Tilavonemab</title>
            <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Study Drug, and Fatal TEAEs</title>
          <description>Treatment emergent adverse events (TEAEs) are defined as any adverse event (AE) from the time of study drug administration until 20 weeks after discontinuation of study drug. An AE is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE (SAE) is defined as any event that: results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome. Severity of AEs was categorized as mild, moderate, or severe. Relationship of the AE to the study treatment was categorized as having a reasonable possibility or no reasonable possibility.</description>
          <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE With a Reasonable Possibility of Relationship to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Discontinuation of Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology: Number of Participants With Postbaseline Potentially Clinically Significant (PCS) Values</title>
        <description>Clinical laboratory PCS criteria were adapted from National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
        <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
        <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>1000 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2000 mg/2000 mg Tilavonemab</title>
            <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO/2000 mg Tilavonemab</title>
            <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology: Number of Participants With Postbaseline Potentially Clinically Significant (PCS) Values</title>
          <description>Clinical laboratory PCS criteria were adapted from National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
          <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin - Low (&lt; 100 g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin - High (&gt; 40 g/L above Upper Limit of Normal [ULN])</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - Low (&lt; 75 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - Low (&lt; 2 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - High (&gt; 100 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils - Low (&lt; 1 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes - Low (&lt; 0.5 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes - High (&gt; 20 × 10^9/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activated Partial Thromboplastin Time (&gt; ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin International Normalized Ratio (&gt; ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Chemistry: Percentage of Participants With Postbaseline PCS Values</title>
        <description>Clinical laboratory PCS criteria were adapted from NCI CTCAE version 4.03</description>
        <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
        <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>1000 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2000 mg/2000 mg Tilavonemab</title>
            <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO/2000 mg Tilavonemab</title>
            <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Chemistry: Percentage of Participants With Postbaseline PCS Values</title>
          <description>Clinical laboratory PCS criteria were adapted from NCI CTCAE version 4.03</description>
          <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Aminotransferase (&gt; 3 × ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (&gt; 3 × ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (&gt; 2.5 × ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (&gt; 1.5 × ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (&gt; 1.5 × ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - Low (&lt; 1.75 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - High (&gt; 3.1 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - Low (&lt; 130 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - High (&gt; 155 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium - Low (&lt; 3 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium - High (&gt; 6 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - Low (&lt; 2.2 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - High (&gt; 13.9 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (&lt; 20 g/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (&gt; 12.92 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (&gt; 5.7 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate (&lt; 0.6 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid (&gt; 590 μmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Columbia-Suicide Severity Rating Scale (C-SSRS) During Double-Blind Treatment Period</title>
        <description>The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.</description>
        <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
        <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>1000 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2000 mg/2000 mg Tilavonemab</title>
            <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO/2000 mg Tilavonemab</title>
            <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Columbia-Suicide Severity Rating Scale (C-SSRS) During Double-Blind Treatment Period</title>
          <description>The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.</description>
          <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal behaviors or ideations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behaviors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideations only (No Suicidal Behavior)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brain Magnetic Resonance Imaging (MRI) Results: Number of Participants With Cerebral Edemas, New Microhemorrhage(s), and Severe White Matter Disease</title>
        <time_frame>Baseline to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
        <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570. Participants with postbaseline value for the respective parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>300 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>1000 mg/1000 mg Tilavonemab</title>
            <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>2000 mg/2000 mg Tilavonemab</title>
            <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PBO/2000 mg Tilavonemab</title>
            <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Magnetic Resonance Imaging (MRI) Results: Number of Participants With Cerebral Edemas, New Microhemorrhage(s), and Severe White Matter Disease</title>
          <population>Safety Data Set: All participants who received at least 1 dose of study drug in Study M15-570. Participants with postbaseline value for the respective parameter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebral Edemas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Questionable Cerebral Edemas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Microhemorrhage(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe White Matter Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality: an overall median of 353.5 days. Serious and Other Adverse Events: From first dose of study drug to 20 weeks after last dose of study drug; overall median time on treatment was 279 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>300 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 300 mg tilavonemab in Study M15-566 received 1000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>1000 mg/1000 mg Tilavonemab</title>
          <description>Participants who received 1000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>2000 mg/2000 mg Tilavonemab</title>
          <description>Participants who received 2000 mg tilavonemab in Study M15-566 were continued on the same dose in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>PBO/2000 mg Tilavonemab</title>
          <description>Participants who received PBO in Study M15-566 received 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>COVID-19 PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>CYSTITIS ESCHERICHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PNEUMONIA LEGIONELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PROCEDURAL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>COLORECTAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGGRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>BEHAVIOUR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>CHRONIC KIDNEY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study M15-570 was discontinued because of lack of efficacy in the parent study (Study M15-566) and 2) the tilavonemab development program was discontinued.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

